You are here:

sildenafil (Revatio)


Following a full submission

sildenafil citrate (Revatio®) is accepted for restricted use within NHS Scotland for treatment of patients with pulmonary arterial hypertension (PAH) classified as WHO functional class II, to improve exercise capacity. Efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease.

It is restricted to initiation by specialists working in the Scottish Pulmonary Vascular Unit or similar specialists.

This is an orphan indication for sildenafil with limited clinical evidence from post-hoc analysis of a short-term clinical trial.

Drug Details

Drug Name: sildenafil (Revatio)
SMC Drug ID: 596/10
Manufacturer: Pfizer Ltd
Indication: Pulmonary arterial hypertension
BNF Category:
Sub Category: 2.5 Hypertension and heart failure
Submission Type: Full submission
Status: Restricted
Date Advice Published: 8 February 2010